Cotización Vortex Energy - VRTX

	Precios en Tiempo Real	Nivel 2
Forex

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

0.05

Postura de Compra

0.05

Postura de Venta

0.055

Volume Operado de la Acción

97,727

0.05 Rango del Día 0.055

0.05 Rango de 52 semanas 0.85

Precio Anterior

0.05

Precio de Apertura

0.055

Hora

5000

0.05

Última hora de negociación

Volumen promedio (3 m)

127,666

Volumen financiero

Precio Promedio Ponderado

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.01	-16.6666666667	0.06	0.06	0.05	118910	0.05350438	CS
4	-0.04	-44.4444444444	0.09	0.09	0.05	173710	0.060912	CS
12	-0.095	-65.5172413793	0.145	0.145	0.05	127666	0.08535349	CS
26	-0.17	-77.2727272727	0.22	0.27	0.05	87018	0.12111039	CS
52	-0.36	-87.8048780488	0.41	0.85	0.05	155309	0.37262337	CS
156	-0.05	-50	0.1	2.32	0.05	199681	0.92090555	CS
260	-0.05	-50	0.1	2.32	0.05	199681	0.92090555	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
METLMetalite Resources Inc	$ 0.05 (400.00%)	620.56k
VCVolatus Capital Corp	$ 0.01 (100.00%)	742k
BEEBee Vectoring Technologies International Inc	$ 0.01 (100.00%)	160k
TRAITrilogy AI Corp	$ 0.09 (63.64%)	36k
CLSHCLS Holdings USA Inc	$ 0.095 (58.33%)	4.53k
CURE.XBiocure Technology Inc	$ 0.01 (-66.67%)	3k
TONETriple One Metals Inc	$ 0.005 (-50.00%)	148.5k
VTALJustera Health Ltd	$ 0.005 (-50.00%)	50k
ENRTEnertopia Corp	$ 0.005 (-50.00%)	29.3k
ACRG.A.UAcreage Holdings Inc	US$ 0.005 (-50.00%)	220.51k
SPMTSpearmint Resources Inc	$ 0.025 (25.00%)	4.34M
CLDVCloud3 Ventures Inc	$ 0.015 (-40.00%)	3.9M
CSSCascada Silver Corp	$ 0.04 (0.00%)	2.21M
PRMEPrime Drink Group Corp	$ 0.315 (0.00%)	2.05M
MILIMilitary Metals Corp	$ 0.375 (8.70%)	1.95M